PTLF — Petlife Pharmaceuticals Share Price
Last trade - 00:00- $0.02m
- $0.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Aug | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The Company specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. The Company has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula. The Company has rights to formulate, package and market a product line, Vitalzul. Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins and minerals. Vitalzul inhibits blood vessels formation in solid tumors. Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. As of August 31, 2016, Escozine (for humans) was sold as either a nutraceutical or prescription drug in 40 countries, including the United States.
Directors
- Last Annual
- August 31st, 2017
- Last Interim
- February 28th, 2018
- Incorporated
- June 26th, 2014
- Public Since
- January 1st, 1970
- No. of Employees
- 2
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 196,751,735
- Address
- 8033 W Sunset Blvd Ste 867, LOS ANGELES, 90046-2401
- Web
- http://www.petlifepharma.com/
- Phone
- +1 4242166807
- Auditors
- LBB Associates, LTD. LLP
Upcoming Events for PTLF
Similar to PTLF
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:39 UTC, shares in Petlife Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Petlife Pharmaceuticals last closed at $0.00 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Petlife Pharmaceuticals share price has underperformed the S&P500 Index by -72.02% over the past year.
There is no consensus recommendation for this security.
Petlife Pharmaceuticals does not currently pay a dividend.
Petlife Pharmaceuticals does not currently pay a dividend.
Petlife Pharmaceuticals does not currently pay a dividend.
To buy shares in Petlife Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Petlife Pharmaceuticals had a market capitalisation of $0.02m.
Here are the trading details for Petlife Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PTLF
Based on an overall assessment of its quality, value and momentum Petlife Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Petlife Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -54.72%.
As of the last closing price of $0.00, shares in Petlife Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Petlife Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Petlife Pharmaceuticals' management team is headed by:
- Sebastian Serrell-Watts - CHM
- Bruce Niswander - CFO
- Vivek Ramana - OTH